Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-blind, Randomized, Placebo-controlled, Multi-center Trial, to Determine the Safety and Antiviral Effect of 14 Days of LCQ908 Monotherapy in Hepatitis C Infected Patients

NCT01387958 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT01387958
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01387958 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-blind, Randomized, Placebo-controlled, Multi-center Trial, to Determine the Safety and Antiviral Effect of 14 Days of LCQ908 Monotherapy in Hepatitis C Infected Patients
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 2
Overall status
Terminated
Start date
July 31, 2011
Completion date
February 29, 2012
Enrollment
32 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c